Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Alejandra Mendez Peralta

General Practice Ponce, PR Medical Doctor

NPI 1164916342 CMS profile 4619477

Po Box 7004, Ponce, PR 00732

Open in the dashboard

General payments

$2,443

63 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Alejandra Mendez Peralta of Ponce, PR is reported in the CMS Open Payments database as having received $2,443 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1
2023 General $711 31
2022 General $1,010 20
2021 General $425 4
2020 General $61 3
2019 General $218 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandra Mendez Peralta
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Alejandra Mendez Peralta were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Alejandra Mendez Peralta General Practice median Middle half National median
2019 $218 $107 $37–$285 $163
2020 $61 $75 $25–$213 $114
2021 $425 $93 $30–$272 $132
2022 $1,010 $103 $36–$279 $149
2023 $711 $106 $34–$276 $160
2024 $19 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $610 20 payments
  2. Neurocrine Biosciences, Inc. $554 7 payments
  3. Janssen Pharmaceuticals, Inc $457 9 payments
  4. Teva Pharmaceuticals USA, Inc. $316 10 payments
  5. Otsuka America Pharmaceutical, Inc. $140 2 payments
  6. Allergan Inc. $106 5 payments
  7. Alkermes, Inc. $84 4 payments
  8. ITI, Inc. $70 3 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $68 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,443 63 payments
Products named General payments · program years 2019–2024
  1. VRAYLAR $610 20 payments
  2. INGREZZA Neurology $333 3 payments
  3. AUSTEDO $236 7 payments
  4. SPRAVATO $235 6 payments
  5. INGREZZA Neuropsychiatry $221 4 payments
  6. REXULTI $140 2 payments
  7. INVEGA SUSTENNA $130 2 payments
  8. INVEGA TRINZA $105 1 payment
  9. INVEGA $92 1 payment
  10. LYBALVI $84 4 payments
  11. Other $697 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record